))
A Discussion with Gil Aharon of Rosalind Advisors: Biotech Investing, Verona Pharma & Delcath Systems
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on October 16, 2023 23:24 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 337249289 series 3380517
A tartalmat a Encode Ideas, L.P., Encode Ideas, and L.P. biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Encode Ideas, L.P., Encode Ideas, and L.P. vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
An interview with Gil Aharon of Rosalind Advisors, where we discuss his perspective on the macro biotech market. Having run a dedicated life science fund for >10 years, Gil puts today's difficult biotech market into historical context and offers his opinion on why investors should be optimistic for the future. During the interview, we also discuss two of Gil's favorite smaller health care names, Verona Pharma and Delcath Systems.
Companies discussed during the podcast;
- Verona Pharma plc (Nasdaq: VRNA)
- Delcath Systems, Inc (Nasdaq: DCTH)
- Immunogen Inc (Nasdaq: IMGN)
Gil Aharon, who is a director of Delcath Systems, Inc. (“Delcath”) appeared on this episode of the podcast. Listeners are urged to review Delcath’s SEC filings and cautioned not to place undue reliance on any forward-looking statements. Delcath undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.
7 epizódok
Megosztás
